Clinically informed intermediate reasoning enables generalizable prostate cancer prognostication through machine learning in limited settings.

This study develops a machine learning–based pipeline to predict prostate cancer prognosis pre‑surgically using biop...

Continue ReadingClinically informed intermediate reasoning enables generalizable prostate cancer prognostication through machine learning in limited settings.

Disitamab vedotin (RC48-ADC) combined with immunotherapy as neoadjuvant therapy for localized muscle-invasive bladder cancer: a multicenter real-world study.

This multicenter retrospective real-world study evaluated neoadjuvant disitamab vedotin (RC48), a HER2-directed antibody...

Continue ReadingDisitamab vedotin (RC48-ADC) combined with immunotherapy as neoadjuvant therapy for localized muscle-invasive bladder cancer: a multicenter real-world study.